evaluating the role of omega 3 on the side effects of isotretinoin in patients with the acnea vulgaris
Clicks: 227
ID: 244407
2017
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
9.9
/100
33 views
33 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Abstract
Background: Acne vulgaris is chronic inflamatory disease of the pilosebaceous unit.Patients experience psychological burdens like depression ,anxiety, and low self- esteem. Isotretinoin is used in the treatment of severe and recalcitrant acne; however, this treatment is associated with a number of partialy common adverse effects that it sometimes may stop the process of treatment. The aim of this study is to evaluate the effect of oral omega 3 on side-effects of isotretinoin .
Materials and Methods: One hundred eighteen patients with severe acne vulgaris were randomly divided into two groups. Control group received isotretinoin (0.5 mg∕kg) alone and case group received isotretinoin (0.5 mg∕kg) combined with omega 3 (2 capsuls) daily. The duration of treatment was 16 weeks.Mucocutaneous side-effects were assessed in patients(4, 8, 12, 16th wk).
Results: Lip dryness (4, 8, 12th wk) and dryness of nose, skin, eye in the 4 th week in the patients with acne vulgaris treated with isotretinoin and omega3 was lesser than in the patients treated with isotretinoin alone, that this difference was statistically significant (p<0.001).
Conclusion: Based on the results of this study, Omega 3 decreased the mucocutaneous side effects in the patients with acne vulgaris who received isotretinoin.
| Reference Key |
mirnezami2017majallah-ievaluating
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Mina Mirnezami |
| Journal | addictive behaviors |
| Year | 2017 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.